Orionis Biosciences is at the forefront of developing innovative therapeutic modalities through its two primary platforms: A-Kine® and ALLO-GLUE™. The A-Kine® platform focuses on engineered cytokines, termed A-Kines, which are designed to selectively activate immune cells while minimizing systemic toxicity. This platform aims to enhance the immune response against cancer by precisely targeting specific cell types, such as dendritic cells, to restore immune functions and elicit effective antitumor activity. By modifying traditional cytokines, Orionis seeks to create a diverse pipeline of immunotherapy candidates that can effectively engage the immune system without the adverse effects commonly associated with conventional cytokine therapies.

The ALLO-GLUE™ platform, on the other hand, is centered around the discovery and design of allosteric molecular glues. These small molecules are engineered to interact with disease targets that have historically been difficult to drug, enabling the modulation, inhibition, or degradation of these targets through cellular mechanisms. This platform employs a high-throughput screening approach to identify potential drug candidates and optimize their interactions with a wide range of proteins. Together, these platforms represent Orionis's commitment to pioneering conditionally active medicines that leverage the body's natural immune mechanisms to combat cancer and other serious diseases.

United States

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Orionis Biosciences

Company Details